Maria A Croyle

Summary

Affiliation: University of Texas
Country: USA

Publications

  1. ncbi Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem
    Maria A Croyle
    The University of Texas at Austin, College of Pharmacy, Division of Pharmaceutics and Institute of Cellular and Molecular Biology, PHR 4 214D, 2409 W University Avenue, Austin, TX 78712 1074, USA
    Expert Opin Drug Metab Toxicol 5:1189-211. 2009
  2. ncbi PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum
    Maria A Croyle
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin Austin, Texas 78712, USA
    J Virol 78:912-21. 2004
  3. ncbi "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung
    M A Croyle
    Institute for Human Gene Therapy and Department of Molecular and Cellular Engineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Virol 75:4792-801. 2001
  4. ncbi Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo
    M A Croyle
    Division of Pharmaceutics, The University of Texas at Austin College of Pharmacy, Austin, TX 78712, USA
    Mol Ther 4:22-8. 2001
  5. ncbi Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism
    Michael P Boquet
    The University of Texas at Austin, College of Pharmacy, Division of Pharmaceutics, Austin, TX 78712 1074, USA
    J Pharmacol Toxicol Methods 58:222-32. 2008
  6. ncbi Utility of PEGylated recombinant adeno-associated viruses for gene transfer
    Hong T Le
    The University of Texas at Austin College of Pharmacy, Division of Pharmaceutics, Austin, TX 78712, United States
    J Control Release 108:161-77. 2005
  7. ncbi Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection
    Shellie M Callahan
    College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, Austin, TX, USA
    Virol J 5:111. 2008
  8. ncbi PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver
    Maria A Croyle
    Institute for Human Gene Therapy and Department of Molecular and Cellular Engineering, University of Pennsylvania, Philadelphia 19104, USA
    Hum Gene Ther 13:1887-900. 2002
  9. ncbi Impact of transgene expression on drug metabolism following systemic adenoviral vector administration
    Shellie M Callahan
    College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, Austin, TX 78712-1074, USA
    J Gene Med 8:566-76. 2006
  10. ncbi Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450
    Shellie M Callahan
    The University of Texas at Austin, College of Pharmacy, PHR 4.214D, 1 University Station A1920, Austin, TX 78712-1074, USA
    J Pharmacol Exp Ther 312:492-501. 2005

Research Grants

  1. Virus-Receptor Interaction and CYP3A Expression
    Maria Croyle; Fiscal Year: 2005

Collaborators

Detail Information

Publications25

  1. ncbi Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem
    Maria A Croyle
    The University of Texas at Austin, College of Pharmacy, Division of Pharmaceutics and Institute of Cellular and Molecular Biology, PHR 4 214D, 2409 W University Avenue, Austin, TX 78712 1074, USA
    Expert Opin Drug Metab Toxicol 5:1189-211. 2009
    ....
  2. ncbi PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum
    Maria A Croyle
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin Austin, Texas 78712, USA
    J Virol 78:912-21. 2004
    ....
  3. ncbi "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung
    M A Croyle
    Institute for Human Gene Therapy and Department of Molecular and Cellular Engineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Virol 75:4792-801. 2001
    ....
  4. ncbi Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo
    M A Croyle
    Division of Pharmaceutics, The University of Texas at Austin College of Pharmacy, Austin, TX 78712, USA
    Mol Ther 4:22-8. 2001
    ..This formulation also enhanced the physical stability of the virus. No significant loss in titer was detected from a lyophilized formulation after storage at 25 degrees C for 30 days...
  5. ncbi Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism
    Michael P Boquet
    The University of Texas at Austin, College of Pharmacy, Division of Pharmaceutics, Austin, TX 78712 1074, USA
    J Pharmacol Toxicol Methods 58:222-32. 2008
    ..25, 1, and 4 days after treatment in the rat. Animals were given 5.7 x 10(12) vp/kg of HAdV-5 expressing beta-galactosidase or saline through a jugular catheter or by direct tail vein injection...
  6. ncbi Utility of PEGylated recombinant adeno-associated viruses for gene transfer
    Hong T Le
    The University of Texas at Austin College of Pharmacy, Division of Pharmaceutics, Austin, TX 78712, United States
    J Control Release 108:161-77. 2005
    ..001). This technology could promote successful readministration of vector in the clinic and marked expression in patients with anti-AAV antibodies...
  7. ncbi Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection
    Shellie M Callahan
    College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, Austin, TX, USA
    Virol J 5:111. 2008
    ..05). CYP2C11 was affected similar manner but recovered by day 14. Microarray and in vitro studies suggest that changes in cellular signaling pathways initiated early in virus infection contribute to changes in CYP...
  8. ncbi PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver
    Maria A Croyle
    Institute for Human Gene Therapy and Department of Molecular and Cellular Engineering, University of Pennsylvania, Philadelphia 19104, USA
    Hum Gene Ther 13:1887-900. 2002
    ..In light of these results, the concept of improving the performance of adenoviral vectors through modification of the capsid with PEG shows promise...
  9. ncbi Impact of transgene expression on drug metabolism following systemic adenoviral vector administration
    Shellie M Callahan
    College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, Austin, TX 78712-1074, USA
    J Gene Med 8:566-76. 2006
    ..The shift in transcription and translation of protein for maintenance of physiologic homeostasis to production of viral proteins and transgene product and their associated toxicity during viral infection may explain our observations...
  10. ncbi Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450
    Shellie M Callahan
    The University of Texas at Austin, College of Pharmacy, PHR 4.214D, 1 University Station A1920, Austin, TX 78712-1074, USA
    J Pharmacol Exp Ther 312:492-501. 2005
    ....
  11. ncbi A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs
    Jin Huk Choi
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States
    Mol Pharm 9:156-67. 2012
    ..SL immunization also reduced systemic anti-Ad5 T and B cell responses in naive mice and those with PEI, suggesting that secondary immunizations could be highly effective for both populations...
  12. ncbi Renal pathophysiology after systemic administration of recombinant adenovirus: changes in renal cytochromes P450 based on vector dose
    Hong T Le
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA
    Hum Gene Ther 17:1095-111. 2006
    ..01). This suggests that changes in renal CYP and corresponding arachidonic acid metabolites may play a role in the documented toxicity associated with the systemic administration of recombinant Ad...
  13. ncbi Controlled inactivation of recombinant viruses with vitamin B2
    Shellie M Callahan
    The University of Texas at Austin, College of Pharmacy, Division of Pharmaceutics, Austin, TX 78712 1074, USA
    J Virol Methods 148:132-45. 2008
    ..Virus exposed to 8-MOP was inactivated in 90 min. DNA and RNA viruses can be inactivated by riboflavin and LWUVI and used in physiological systems sensitive to other photochemicals...
  14. ncbi Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice
    Maria A Croyle
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA
    PLoS ONE 3:e3548. 2008
    ....
  15. ncbi PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile
    M A Croyle
    College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, TX 78712, USA
    Gene Ther 12:579-87. 2005
    ..1+/-0.4 x 10(5) pg/mg protein, P=0.0001). This suggests that PEGylation of HD-Ad vectors may be appropriate for their safe and efficient use in the clinic...
  16. ncbi Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus
    Piyanuch Wonganan
    Division of Pharmaceutics, College of Pharmacy, and Institute of Cellular and Molecular Biology, The University of Texas at Austin, Austin, Texas 78712, USA
    Mol Pharm 8:78-92. 2011
    ....
  17. ncbi Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity
    Jin Huk Choi
    Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin, Austin, Texas, USA
    Clin Vaccine Immunol 19:84-95. 2012
    ..Additional studies with these and other virus-antibody ratios may be useful to predict and model the type of immune responses generated against a transgene in those with different levels of exposure to adenovirus...
  18. ncbi PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route
    Xuan Cheng
    College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, Austin, Texas 78712, USA
    Pharm Res 20:1444-51. 2003
    ..CONCLUSIONS: PEGylated adenoviruses are suitable gene delivery vehicles for oral administration...
  19. ncbi Development of a nasal adenovirus-based vaccine: Effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices
    Sandra S Renteria
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA
    Vaccine 28:2137-48. 2010
    ..Formulations prevented aggregation during actuation, freeze-thaw and long-term storage. The device, formulation and dose may significantly influence aggregation and potency of any nasal adenovirus 5-based vaccine...
  20. ncbi Development of formulations that enhance physical stability of viral vectors for gene therapy
    M A Croyle
    The University of Texas at Austin College of Pharmacy, Division of Pharmaceutics, Austin, TX 78712, USA
    Gene Ther 8:1281-90. 2001
    ..In summary, lyophilized preparations that can be shipped and stored at 25 degrees C offer a solution to the current problem of distribution of viral vectors for clinical trials...
  21. ncbi PEGylated Adenoviruses: From Mice to Monkeys
    Piyanuch Wonganan
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA E mail
    Viruses 2:468-502. 2010
    ..Specific emphasis is placed on the application of this technology to the adenovirus, the most potent viral vector with the most highly characterized toxicity profile to date, in several animal models...
  22. ncbi Factors that influence stability of recombinant adenoviral preparations for human gene therapy
    M A Croyle
    College of Pharmacy, University of Michigan, Ann Arbor 48109 1065, USA
    Pharm Dev Technol 3:373-83. 1998
    ..Both formulations provided adequate stability for the adenovirus, with 2.6 and 5.6 x 10(11) lfu/ml detected 150 days after drying, respectively...
  23. ncbi Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model
    P Wonganan
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712 1074, USA
    Cancer Gene Ther 16:405-14. 2009
    ....
  24. ncbi Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine
    M A Croyle
    College of Pharmacy, The University of Michigan, Ann Arbor 48109 1065, USA
    Pharm Res 15:1348-55. 1998
    ..In this report, various cyclodextrin formulations were tested for their ability to enhance adenoviral transduction efficiency in two models of the intestinal epithelium: differentiated Caco-2 cells and rat jejunum...
  25. ncbi Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery
    M A Croyle
    College of Pharmacy, University of Michigan, Ann Arbor 48109 1065, USA
    Pharm Dev Technol 3:365-72. 1998
    ..This approach will not only simplify the preparation of adenoviral vectors for in vivo studies and clinical trials, but will facilitate production of stable adenoviral formulations for oral gene delivery...

Research Grants2

  1. Virus-Receptor Interaction and CYP3A Expression
    Maria Croyle; Fiscal Year: 2005
    ....